viewe-Therapeutics plc

E-Therapeutics chief says drug candidate has hit a “sweet spot”

E-Therapeutics (LON:ETX) chief executive Malcolm Young tells Proactive that the firm has hit the “sweet spot” on the drug candidate ETS6103 following its latest test results.

The Phase IIb study, which was a larger study at a lower dose showed the drug was a little bit off the efficacy of its rival amitriptyline, but was still effective.

But the firm has previously completed a Phase IIa study on ETS6103, which was carried out on a small number of patients at a higher dose, showing the drug had the same efficacy as its closest rival.

Young says that the drug has a “cleaner profile” than amitriptyline, and adds that “across the two studies, we are pleased.”

Quick facts: e-Therapeutics plc

Price: 3.25 GBX

Market: AIM
Market Cap: £8.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...



Holding(s) in Company

4 weeks ago

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read